Wendelboe A, Weitz JI (2024) Global health burden of venous thromboembolism. Arterioscler Thromb Vasc Biol 44(5):1007–1011

Article  CAS  PubMed  Google Scholar 

Miller KD, Nogueira L, Devasia T et al (2022) Cancer treatment and survivorship statistics, 2022. CA Cancer J Clin 72(5):409–436

Article  PubMed  Google Scholar 

Mulder FI, Horváth-Puhó E, van Es N et al (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959–1969

Article  CAS  PubMed  Google Scholar 

Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634

Article  CAS  PubMed  Google Scholar 

Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA (2000) Prognosis of cancers associated with venous thromboembolism. N Engl J Med 343(25):1846–1850

Article  PubMed  Google Scholar 

Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH (2006) Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol 24(3):484–490

Article  PubMed  Google Scholar 

Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458–464

Article  PubMed  Google Scholar 

Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH (2007) Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 110(10):2339–2346

Article  PubMed  Google Scholar 

Chew HK, Wun T, Harvey DJ, Zhou H, White RH (2007) Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol 25(1):70–76

Article  PubMed  Google Scholar 

Agnelli G, Bolis G, Capussotti L et al (2006) A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg 243(1):89–95

Article  PubMed  PubMed Central  Google Scholar 

Konstantinides SV, Meyer G, Becattini C et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41(4):543–603

Article  PubMed  Google Scholar 

Stevens SM, Woller SC, Kreuziger LB et al (2021) Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):e545–e608

Article  CAS  PubMed  Google Scholar 

Lyman GH, Carrier M, Ay C et al (2021) American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927–974

Article  CAS  PubMed  PubMed Central  Google Scholar 

Streiff MB, Holmstrom B, Angelini D et al (2024) Cancer-Associated venous thromboembolic disease, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 22(7):483–506

Article  CAS  PubMed  Google Scholar 

Farge D, Frere C, Connors JM et al (2022) 2022 International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334–e347

Article  CAS  PubMed  PubMed Central  Google Scholar 

Key NS, Khorana AA, Kuderer NM et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41(16):3063–3071

Article  CAS  PubMed  Google Scholar 

Muka T, Glisic M, Milic J et al (2020) A 24-step guide on how to design, conduct, and successfully publish a systematic review and meta-analysis in medical research. Eur J Epidemiol 35(1):49–60

Article  PubMed  Google Scholar 

van Hylckama Vlieg MAM, Nasserinejad K, Visser C et al (2023) The risk of recurrent venous thromboembolism after discontinuation of anticoagulant therapy in patients with cancer-associated thrombosis: a systematic review and meta-analysis. EClinicalMedicine 64:102194

Article  PubMed  PubMed Central  Google Scholar 

Moik F, Colling M, Mahé I, Jara-Palomares L, Pabinger I, Ay C (2022) Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review. J Thromb Haemost 20(3):619–634

Article  PubMed  Google Scholar 

Schmidt RA, Al Zaki A, Desilet N et al (2020) Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism. Thromb Res 188:106–114

Article  CAS  PubMed  Google Scholar 

de Winter MA, Büller HR, Carrier M et al (2023) Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score. Eur Heart J 44(14):1231–1244

Article  PubMed  PubMed Central  Google Scholar 

Louzada ML, Carrier M, Lazo-Langner A et al (2012) Development of a clinical prediction rule for risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism. Circulation 126:448–454

Article  PubMed  Google Scholar 

Nishimoto Y, Yamashita Y, Morimoto T et al (2020) Predictive ability of modified Ottawa score for recurrence in patients with cancer-associated venous thromboembolism: from the COMMANDVTE registry. Thromb Res 191:66–75

Article  CAS  PubMed  Google Scholar 

Delluc A, Miranda S, Exter PD et al (2020) Accuracy of the Ottawa score in risk stratification of recurrent venous thromboembolism in patients with cancer-associated venous thromboembolism: a systematic review and meta-analysis. Haematologica 105:1436–1442

Article  PubMed  PubMed Central  Google Scholar 

Xiong W, Yamashita Y, Morimoto T et al (2024) Utility of the modified Ottawa score for identification of more preferable candidates of extended anticoagulation therapy in cancer-associated isolated distal deep vein thrombosis: insight from the ONCO DVT study. J Thromb Haemost 22(12):3542–3551

Article  CAS  PubMed  Google Scholar 

Francis CW, Kessler CM, Goldhaber SZ et al (2015) Treatment of venous thromboembolism in cancer patients with Dalteparin for up to 12 months: the DALTECAN study. J Thromb Haemost 13(6):1028–1035

Article  CAS  PubMed  Google Scholar 

Jara-Palomares L, Solier-Lopez A, Elias-Hernandez T et al (2017) Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study. Thromb Res 157:90–96

Article  CAS  PubMed  Google Scholar 

Raskob GE, van Es N, Verhamme P et al (2018) Edoxaban for the treatment of Cancer-Associated venous thromboembolism. N Engl J Med 378(7):615–624

Article  CAS  PubMed  Google Scholar 

Schrag D, Uno H, Rosovsky R et al (2023) Direct oral anticoagulants vs Low-Molecular-Weight heparin and recurrent VTE in patients with cancer: A randomized clinical trial. JAMA 329(22):1924–1933

Article  CAS  PubMed  PubMed Central  Google Scholar 

Di Nisio M, van Es N, Carrier M et al (2019) Extended treatment with Edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. J Thromb Haemost 17(11):1866–1874

Article  PubMed  Google Scholar 

Marshall A, Levine M, Hill C et al (2020) Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus Rivaroxaban randomization of the SELECT-D trial (SELECT-D: 12m). J Thromb Haemost 18(4):905–915

Article  CAS  PubMed  Google Scholar 

Bernardi E, Camporese G, Bortoluzzi C et al (2022) Safety and efficacy of Rivaroxaban as Extended-Phase anticoagulation in patients with Cancer and venous thromboembolism: A preliminary data analysis from the Mac project. Life (Basel) 12(11):1725